Bausch + Lomb Corp
BLCO16.950USD
+0.050+0.30%
收盤 12/19, 16:00（美東）報價延遲15分鐘
6.00B總市值
虧損本益比TTM
關於 Bausch + Lomb Corp 公司
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Bausch + Lomb Corp簡介
公司代碼BLCO
公司名稱Bausch + Lomb Corp
上市日期May 06, 2022
CEOSaunders (Brenton L)
員工數量13500
證券類型Ordinary Share
年結日May 06
公司地址520 Applewood Crescent
城市VAUGHAN
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Canada
郵編L4K 4B4
電話19082552864
網址https://ir.bausch.com/
公司代碼BLCO
上市日期May 06, 2022
CEOSaunders (Brenton L)
Bausch + Lomb Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
股東統計
更新時間: 11月22日 週六
更新時間: 11月22日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
其他
8.54%
持股股東
持股股東
佔比
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
其他
8.54%
股東類型
持股股東
佔比
Corporation
87.66%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.07%
Research Firm
1.67%
Investment Advisor
1.65%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bausch Health Companies Inc
310.45M
87.68%
--
--
Mar 24, 2025
Deutsche Bank Securities Inc.
3.41M
0.96%
-89.90K
-2.57%
Jun 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
2.52M
0.71%
+2.52M
--
Jun 30, 2025
GoldenTree Asset Management, LP
2.58M
0.73%
+334.92K
+14.90%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
+728.68K
+38.79%
Jun 30, 2025
Fidelity Management & Research Company LLC
771.84K
0.22%
+771.84K
--
Jun 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
+1.05M
+210.77%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
查看更多
Ballast Small/Mid Cap ETF
佔比1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
佔比0.03%
BNY Mellon US Small Cap Core Equity ETF
佔比0.03%
Schwab Fundamental International Small Equity ETF
佔比0%
Goldman Sachs MarketBeta US 1000 Equity ETF
佔比0%
Invesco Zacks Mid-Cap ETF
佔比0%
QRAFT AI-Enhanced US Large Cap ETF
佔比0%
AltShares Event-Driven ETF
佔比0%
DFA Dimensional International Core Equity 2 ETF
佔比0%
BNY Mellon US Mid Cap Core Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Bausch + Lomb Corp的前五大股東是誰？
Bausch + Lomb Corp的前五大股東如下：
Bausch Health Companies Inc持有股份：310.45M佔總股份比例：87.68%。
Deutsche Bank Securities Inc.持有股份：3.41M佔總股份比例：0.96%。
Alberta Investment Management Corporation持有股份：3.27M佔總股份比例：0.92%。
Oaktree Capital Management, L.P.持有股份：2.52M佔總股份比例：0.71%。
GoldenTree Asset Management, LP持有股份：2.58M佔總股份比例：0.73%。
Bausch Health Companies Inc持有股份：310.45M佔總股份比例：87.68%。
Deutsche Bank Securities Inc.持有股份：3.41M佔總股份比例：0.96%。
Alberta Investment Management Corporation持有股份：3.27M佔總股份比例：0.92%。
Oaktree Capital Management, L.P.持有股份：2.52M佔總股份比例：0.71%。
GoldenTree Asset Management, LP持有股份：2.58M佔總股份比例：0.73%。
Bausch + Lomb Corp的前三大股東類型是什麼？
Bausch + Lomb Corp 的前三大股東類型分別是：
Bausch Health Companies Inc
Icahn Enterprises LP
Deutsche Bank Securities Inc.
Bausch Health Companies Inc
Icahn Enterprises LP
Deutsche Bank Securities Inc.
有多少機構持有Bausch + Lomb Corp(BLCO)的股份？
截至2025Q4，共有247家機構持有Bausch + Lomb Corp的股份，合計持有的股份價值約為42.63M，占公司總股份的17.16% 。與2025Q3相比，機構持股有所增加，增幅為-2.27%。
哪個業務部門對Bausch + Lomb Corp的收入貢獻最大？
在FY2025Q2，OTC業務部門對Bausch + Lomb Corp的收入貢獻最大，創收482.00M，占總收入的37.72% 。
